I have no personal experience with its use but it was approved for use in Europe and by FDA in US in 2014 for type 2 DM. A sodium glucose co- transporter 2 (SGLT-2) inhibitor said to give good glycaemic control as an add on to other drugs. It acts by inhibiting glucose reabsorption in the kidneys causing glucose loss in urine. Side effects like worsening renal fuction, genital fungal infections and euglycaemic DKA have been described. Post marketing surveys are ongoing...

Empagliflozin is one of three approved sodium-glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus. It lowers blood glucose by reducing reabsorption of glucose in the kidney, which leads to increased urinary excretion of glucose.

Please check

1. Frampton JE.Empagliflozin: A Review in Type 2 Diabetes.Drugs. 2018 Jul;78(10):1037-1048. doi: 10.1007/s40265-018-0937-z.

2. Levine MJ. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev. 2017;13(4):405–423. doi:10.2174/1573399812666160613113556

3. Levine MJ.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev. 2017;13(4):405-423. doi: 10.2174/1573399812666160613113556.

Dear Mohammad,

In EMPA-REG OUTCOME study we have seen a significant reduction of a primary CV endpoint with a glucose-lowering agent. In this study, the primary outcome (CV mortality, non-fatal myocardial infarction and non-fatal stroke) was reduced by empagliflozin compared with placebo. Empagliflozin also reduced all-cause mortality. Other non-adjudicated measures of HF outcomes were similarly reduced including investigator reported HF, the introduction of loop diuretics and death from HF. In the analysis of renal outcomes, incident or worsening nephropathy was reduced for empagliflozin compared with placebo, as well as significantly the reduction the risk of progression to macroalbuminuria and doubling of creatinine.

the EMPA-REG OUTCOME study have shown a significant reduction of a primary CV endpoint in patients with type 2 diabetes on this agent.

In addition, it is safe in patients with CKD with GFR more than 30

There is a significant reduction of a primary CV endpoint with a glucose-lowering agent. In this study, the primary outcome (CV mortality, non-fatal myocardial infarction and non-fatal stroke) was reduced by empagliflozin compared with placebo. Empagliflozin also reduced all-cause mortality.